Table 4.
Percentage of participants with anti-S. sonnei LPS serum IgG ≥268 EU/mL, geometric mean concentrations and geometric mean ratios by time point (per-protocol set).
| % ≥268 EU/mL (95% CI) |
GMC [EU/mL] (95% CI) |
GMR (95% CI) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 1790GAHB group (N = 32) | Placebo group (N = 28) | 1790GAHB group (N = 32) | Placebo group (N = 28) | Ratio | 1790GAHB group (N = 32) | Placebo group (N = 28) | |||
| D1 | 31 (16; 50) | 21 (8; 41) | 97·63 (59·87; 159·21) | 130·47 (81·06; 209·98) | – | – | |||
| D8 | 47 (29; 65) | 18 (6; 37) | 227·24 (130·55; 395·55) | 136·83 (89·21; 209·87) | D8/D1 | 2·33 (1·65; 3·28) | 1·05 (0·95; 1·16) | ||
| D29 | 69 (50; 84) | 21 (8; 41) | 503·89 (283·91; 894·29) | 133·09 (82·89; 213·71) | D29/D1 | 5·16 (3·50; 7·61) | 1·02 (0·91; 1·14) | ||
| D36 | 66 (47; 81) | 18 (6; 37) | 558·81 (324·54; 962·18) | 132·62 (84·17; 208·95) | D36/D1 | 5·72 (3·99; 8·21) | 1·02 (0·93; 1·11) | ||
| D57 | 69 (50; 84) | 21 (8; 41) | 506·48 (293·97; 872·60) | 141·43 (90·39; 221·29) | D57/D1 | 5·19 (3·73; 7·21) | 1·08 (0·98; 1·19) | ||
| D64 | 69 (50; 84) | 39 (22; 59) | 560·95 (317·73; 990·36) | 196·53 (127·59; 302·71) | D64/D57 | 1·11 (0·94; 1·31) | 1·39 (1·09; 1·77) | ||
| D85* | 84 (66; 95) | 65 (44; 83) | 1050·25 (618·67; 1782·92) | 742·37 (379·46; 1452·38) | D85/D57 | 2·03 (1·37; 2·99) | 5·32 (2·91; 9·73) | ||
LPS, lipopolysaccharide; IgG, immunoglobulin G; EU, enzyme-linked immunosorbent assay units; N, number of participants; GMC, geometric mean concentration; GMR, within-subjects geometric mean ratio; D, day; CI; confidence interval. *N = 31 in the 1790GAHB group and N = 26 in the Placebo group.